Literature DB >> 10225536

Epidemiology of NSAID induced gastrointestinal complications.

G Singh1, G Triadafilopoulos.   

Abstract

Nonsteroidal antiinflammatory drugs (NSAID) are one of the most commonly used classes of medications worldwide. It is estimated that more than 30 million people take NSAID daily. Gastrointestinal (GI) complications related to NSAID therapy are the most prevalent category of adverse drug reactions. Patients with arthritis are among the most frequent users of NSAID and are therefore particularly at risk for these side effects. To evaluate the nature of NSAID-related GI complications and to determine how their frequency can be reduced, a series of studies of such complications in patients with rheumatic disease have been carried out based on data from the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS). This report briefly reviews the literature and presents recent findings from the ARAMIS studies, which provide an update on published information. It addresses whether GI side effects such as dyspepsia can serve as warning symptoms for life-threatening GI complications and describes the risk factors for these events. It also summarizes a study that investigated whether H2-receptor antagonists and antacids affect the development of serious GI complications. In addition, ongoing research and topics to be addressed in future studies are described.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225536

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  103 in total

1.  Three decades of research on computer applications in health care: medical informatics support at the Agency for Healthcare Research and Quality.

Authors:  J Michael Fitzmaurice; Karen Adams; John M Eisenberg
Journal:  J Am Med Inform Assoc       Date:  2002 Mar-Apr       Impact factor: 4.497

Review 2.  Selective COX-2 inhibitors: a health economic perspective.

Authors:  David L B Schwappach; Christian M Koeck
Journal:  Wien Med Wochenschr       Date:  2003

3.  Lactobacillus protected bone damage and maintained the antioxidant status of liver and kidney homogenates in female wistar rats.

Authors:  Sarika Amdekar; Avnish Kumar; Poonam Sharma; Rambir Singh; Vinod Singh
Journal:  Mol Cell Biochem       Date:  2012-06-04       Impact factor: 3.396

Review 4.  Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity.

Authors:  Luis M Ruilope; Antonio Coca; José R Banegas; Jose Luis Pablos; Manuel Luque
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

5.  Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals.

Authors:  V Bongard; S Ménard-Taché; H Bagheri; K Kabiri; M Lapeyre-Mestre; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

6.  British Journal of Clinical Pharmacology review series. Clinical research methods in gastroenterology.

Authors:  Marjorie M Walker; Brendan J R Whittle
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 7.  The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.

Authors:  Tony Zhang; Aleem Adatia; Wasifa Zarin; Misha Moitri; Abi Vijenthira; Rong Chu; Lehana Thabane; Walter Kean
Journal:  Inflammopharmacology       Date:  2010-11-13       Impact factor: 4.473

8.  Reconstruction of cyclooxygenase evolution in animals suggests variable, lineage-specific duplications, and homologs with low sequence identity.

Authors:  Justin C Havird; Kevin M Kocot; Pamela M Brannock; Johanna T Cannon; Damien S Waits; David A Weese; Scott R Santos; Kenneth M Halanych
Journal:  J Mol Evol       Date:  2015-03-11       Impact factor: 2.395

Review 9.  Does cyclooxygenase-2 affect blood pressure?

Authors:  Hui-Fang Cheng; Raymond C Harris
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 10.  [Paracetamol. Efficacious and safe for all ages].

Authors:  M Wehling
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.